We expect Amgen AMGN to beat expectations when it reports second-quarter 2025 results on Aug. 5 after market close. In the ...

ICE-T Conference presenters explain what nurses and APPs should take into account as immune cell effector therapies become ...

The trial will test several treatment approaches in the maintenance setting for extensive stage small cell lung cancer.

Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

IMDELLTRA is a first-in-class targeted immunotherapy engineered by Amgen. A pharmacist filling a prescription for a complex drug developed by the company.

Amgen Inc. (NASDAQ: AMGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 2, Amgen announced new interim results from the global Phase 3 DeLLphi-304 trial for its drug IMDELLTRA ...

AMGN's Imdelltra slashes lung cancer death risk by 40% in Phase III, extending survival by over five months compared to chemotherapy.

Administer IMDELLTRA ® in an appropriate health care facility equipped to monitor and manage CRS. Ensure patients are well hydrated prior to administration of IMDELLTRA ®.